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A Double-blind, Randomized, Placebo Controlled Trial of Ramelteon for the Treatment of 
Insomnia and Mood Stability in Patients with Euthymic Bipolar Disorder
Edward Norris, MD FAPM, Karen Burke RN, Julia Correll, Ken Zemanek, MD, Joel Lerman, MD, Michael Kaufmann, MD, Lehigh Valley Health Network, Allentown, Pennsylvania
Results
90 individuals signed informed consent and 83 participants were enrolled in the study and were 
randomized to receive ramelteon (n = 42) or placebo (n = 41). There was no evidence of group 
differences on background variables; nor were there differences between groups on any of the 
measures used to monitor disease progression, including PSQI, YMRS, MADRS, or CGI. Overall, 
there were 40 patients who relapsed (48.2%). The results of the Cox regression analyses 
 indicated that the ramelteon group (Odds Ratio 0.48, p=.024) was signifi cantly less likely to 
 relapse over the course of the 24 week study than patients in the placebo group. Kaplan Meier 
curves also indicated signifi cantly longer median survival times in the drug group (Mdn = 188 
days since baseline) versus the placebo group (Mdn=84 days since baseline) X2(1) = 5.33, 




n=42 x2 df p
n (%) n (%)
Lithium 8 (19.5) 7 (16.7) 0.11 1 0.74
Lamotrigine 16 (39.0) 17 (40.5) 0.02 1 0.89
Valproate 4 (9.8) 6 (14.3) 0.4 1 0.53
Carbamazepine/Oxycarbamazepine 4 (9.8) 3 (7.1) 0.18 1 0.67
Atypical mood stabilizers 4 (9.8) 3 (7.1) 0.18 1 0.67
Seroquel or Zyprexa 13 (31.7) 8 (19.2) 1.76 1 0.19
Other Atypical Antipsychotics 12 (29.3) 11 (26.2) 0.1 1 0.75
Antipsychotics 2 (4.9) 1 (2.4) 0.37 1 0.54
Antidepressants 29 (70.7) 28 (66.7) 0.16 1 0.69
Stimulants 6 (14.6) 7 (16.7) 0.07 1 0.8
Anxiolytics/sedatives/hypnotics 22 (53.7) 24 (57.1) 0.1 1 0.75
Total mood stabilizers 31 (75.6) 30 (71.4) 0.19 1 0.67
Total Atypical antipsychotics 23 (56.1) 19 (45.2) 0.98 1 0.32
Total on evidence-based bipolar 
depression medications 26 (63.4) 25 (59.6) 0.13 1 0.72
Purpose
Abnormalities in circadian rhythms are 
prominent features of bipolar I disorder 
(BPD). Literature suggests that disrupted 
24-hour sleep-wake circadian rhythms are 
associated with an increased risk of relapse 
in bipolar disorder. Bipolar patients have 
shorter, and more variable, circadian activity 
patterns even when not acutely ill. It is 
 proposed that normalizing the circadian 
rhythm pattern of bipolar patients will 
 improve their sleep; and consequently, 
also lead to fewer mood exacerbations. 
 Ramelteon offers a mechanism to re- 
synchronize the suprachiasmatic nucleus. 
The administration of ramelteon for bipolar 
patients will improve sleep and will cause 
fewer mood exacerbations.
Methods
This single-site, double-blind, randomized, 
placebo-controlled study evaluated the 
 effi cacy of ramelteon in the treatment of 
 insomnia and mood stability in patients with 
euthymic bipolar disorder for up 6 months of 
maintenance treatment. Men and women aged 
18 to 65 who were currently experiencing 
sleep diffi culties were randomized to receive 
ramelteon or placebo in double blind fashion. 
Sleep (PSQI) and mood symptoms (MADRS, 
YMRS) were evaluated at 4 week intervals. 
Conclusions
This is the fi rst study to examine the 
 potential of ramelteon at treating sleep and 
mood in patients with bipolar disorder. The 
present study shows that ramelteon was 
very effective in maintaining stability for 
 individuals with bipolar disorder. Patients 
treated with ramelteon were approximately 
50% more likely to remain stable throughout 
the trial. In other words, ramelteon treated 
participants were about twice as likely not 
to become depressed or manic during the 






























 Completed Depressed Mixed Manic Withdrew
p = 0.031 p = 0.068
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Ramelteon
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Odds of relapse (p=0.024)






(n=41) Drug (n=42) Total
n (%) n (%) n (%) x2 df p
Gender: .02 1 1.0
female 26 (63.4) 26 (61.9) 52 (62.7)
male 15 (36.6) 16 (38.1) 31 (37.3)
Race: 1.33 2 0.51
African Am 1 (2.4)* 2 (4.8)* 3 (3.6)*
white-euro 40 (97.6) 39 (92.9) 79 (95.2)
white-S. Am 0 (.0)** 1 (2.4)** 1 (1.2)*
Minority status: 1.00 1 0.62
non-minority 40 (97.6) 39 (92.9) 79 (95.2)
minority 1 (2.4)* 3 (7.1)* 4 (4.8)*
Ethnicity: .99 1 1.0 
not hispanic 41 (100) 41 (97.6) 82 (98.8)
hispanic 0 (0)** 1 (2.4)** 1 (1.2)*
Diagnosis BP 41 (100) 42 (100) 83 (100) - - -
Most recent 
episode: 1.67 3 0.64
unknown 1 (2.4)** 0 (0)** 1 (1.2)*
manic 7 (17.1) 10 (23.8) 17 (20.5)
depressed 17 (41.5) 15 (35.7) 32 (38.6)
mixed 16 (39.0) 17 (40.5) 33 (39.8)
M (SD) M (SD) t df p
Age (years) 45.2 (10.8) 46.6 (11.0) -.57 81 0.57
Background Characteristics by Study Assignment
Am = American
*  expected count less than 5; and ** expected count less than 1, both of which render the test statistic 
suspect occur for an entire row (however, it is clear from the small numbers that it is impossible to 
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